[Fundamental and clinical studies on T-1982 (cefbuperazone) in the field of obstetrics and gynecology].
Fundamental and clinical studies on T-1982 (cefbuperazone), a new cephamycin antibiotic, were carried out, and the following results were obtained. When T-1982 was administered at a dose of 1 g by intravenous drip infusion for 30 minutes or 1 hour, the concentration in serum showed as high as 23.0 micrograms/ml or 25.0 micrograms/ml even 2 hours after administration. The concentrations in the genital tissues about 5 hours after administration ranged 1.2-45.6 micrograms/g for 30 minutes drip infusion and 0.9-26.8 micrograms/g for 1 hour drip infusion. From these results, T-1982 was supposed to maintain the in vivo concentration to inhibit 80-100% the growth of bacteria such as S. aureus, E. coli, Klebsiella, Proteus, S. marcescens and Gram-negative anaerobic bacteria, B. fragilis which were often isolated clinically in the field of obstetrics and gynecology. When T-1982 was administered at a dose of 1-2 g twice a day to 14 patients with female genital infection; 2 intrauterine infection, 2 pyometra, 7 pelveoperitonitis, 1 adnexitis, 1 adnexal abscess and 1 vaginal cuff abscess, the clinical results were excellent in 9, effective in 4 and poor in 1. The efficacy rate was 92.9%. No side effects nor abnormalities in laboratory findings were observed in any of the 14 cases. These results suggest that T-1982 has efficacy for the treatment of obstetrical and gynecological infections.
D000038:Abscess / Q000188:drug therapy; D000328:Adult; D002513:Cephamycins / Q000032:analysis* / Q000627:therapeutic use; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010053:Ovary / Q000032:analysis*; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D014599:Uterus / Q000032:analysis* / Q000098:blood supply
D002513:Cephamycins; C035978:cefbuperazone